FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 358:999-1008 March 6, 2008 Number 10 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Supplementary Material Purchase this article Editorial by Shurin, S. B. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background Genetic variants of the enzyme that metabolizes warfarin, cytochrome P-450 2C9 (CYP2C9), and of a key pharmacologic target of warfarin, vitamin K epoxide reductase (VKORC1), contribute to differences in patients' responses to various warfarin doses, but the role of these variants during initial anticoagulation is not clear.

Methods In 297 patients starting warfarin therapy, we assessed CYP2C9 genotypes (CYP2C9 *1, *2, and *3), VKORC1 haplotypes (designated A and non-A), clinical characteristics, response to therapy (as determined by the international normalized ratio [INR]), and bleeding events. The study outcomes were the time to the first INR within the therapeutic range, the time to the first INR of more than 4, the time above the therapeutic INR range, the INR response over time, and the warfarin dose requirement.

Results As compared with patients with the non-A/non-A haplotype, patients with the A/A haplotype of VKORC1 had a decreased time to the first INR within the therapeutic range (P=0.02) and to the first INR of more than 4 (P=0.003). In contrast, the CYP2C9 genotype was not a significant predictor of the time to the first INR within the therapeutic range (P=0.57) but was a significant predictor of the time to the first INR of more than 4 (P=0.03). Both the CYP2C9 genotype and VKORC1 haplotype had a significant influence on the required warfarin dose after the first 2 weeks of therapy.

Conclusions Initial variability in the INR response to warfarin was more strongly associated with genetic variability in the pharmacologic target of warfarin, VKORC1, than with CYP2C9.

Source Information

From the Departments of Medicine and Pharmacology (U.I.S., A.F.-A., R.B.K., D.M.R., C.M.S.), the Department of Molecular Physiology and Biophysics and the Center for Human Genetics Research (M.D.R., Y.B., S.M.D.), and the Department of Biostatistics (C.L.), Vanderbilt University School of Medicine, Nashville.

Full Text of this Article

This article has been cited by other articles:

• (2008). Warfarin Dose Modification by Genotyping. JWatch Oncology and Hematology 2008: 1-1 [Full Text]  
• (2008). All you need to read in the other general journals. BMJ 336: 582-583 [Full Text]  
• Shurin, S. B., Nabel, E. G. (2008). Pharmacogenomics -- Ready for Prime Time?. NEJM 358: 1061-1063 [Full Text]